Project ECHO and primary care buprenorphine treatment for opioid use disorder: Implementation and clinical outcomes
Authors
Anderson, James B.Martin, Stephen A.
Gadomski, Anne
Krupa, Nicole
Mullin, Daniel J.
Cahill, Amber
Jenkins, Paul
UMass Chan Affiliations
Center for Integrated Primary CareDepartment of Family Medicine and Community Health
Document Type
Journal ArticlePublication Date
2021-06-04Keywords
Opioid use disorderProject ECHO
buprenorphine
medication assisted treatment
medications for opioid use disorder
primary care
treatment retention rate
Community Health and Preventive Medicine
Health Services Administration
Integrative Medicine
Primary Care
Psychiatry and Psychology
Substance Abuse and Addiction
Metadata
Show full item recordAbstract
Background: Our rural health system sought to (1) increase the number of primary care clinicians waivered to prescribe buprenorphine for treatment of opioid use disorder (OUD) and (2) consequently increase the number of our patients receiving this treatment. Methods: We used the Project for Extension for Community Health Outcomes (ECHO) tele-education model as an implementation strategy. We examined the number of clinicians newly waivered, the number of patients treated with buprenorphine, the relationship between clinician engagement with ECHO training and rates of buprenorphine prescribing, and treatment retention at 180 days. Results: The number of clinicians with a waiver and number of patients treated increased during and after ECHO training. There was a moderate correlation between the number of ECHO sessions attended by a clinician and number of their buprenorphine prescriptions (r = 0.50, p = 0.01). The 180-day retention rate was 80.7%. Conclusions: Project ECHO was highly effective for increasing access to this evidence-based treatment. The high retention rate in this rural context indicates that most patients are increasing their likelihood of favorable outcomes.Source
Anderson JB, Martin SA, Gadomski A, Krupa N, Mullin D, Cahill A, Jenkins P. Project ECHO and primary care buprenorphine treatment for opioid use disorder: Implementation and clinical outcomes. Subst Abus. 2021 Jun 4:1-9. doi: 10.1080/08897077.2021.1931633. Epub ahead of print. PMID: 34086529. Link to article on publisher's site
DOI
10.1080/08897077.2021.1931633Permanent Link to this Item
http://hdl.handle.net/20.500.14038/29861PubMed ID
34086529Related Resources
Rights
© 2021 The Author(s). This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.Distribution License
http://creativecommons.org/licenses/by-nc-nd/4.0/ae974a485f413a2113503eed53cd6c53
10.1080/08897077.2021.1931633
Scopus Count
Except where otherwise noted, this item's license is described as © 2021 The Author(s). This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.